1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
Joshua M. Lang(University of Wisconsin–Madison), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), H. Xiao(Memorial Sloan Kettering Cancer Center), Hamid Emamekhoo(University of Wisconsin Carbone Cancer Center), K. Autio(Memorial Sloan Kettering Cancer Center), Susan F. Slovin(Cornell University), Jamie M. Sperger(University of Wisconsin–Madison), D.M. Nanus(Cornell University), Wassim Abida(Memorial Sloan Kettering Cancer Center), S.T. Tagawa(Cornell University), Scott M. Dehm(University of Minnesota), A.M. Molina(Cornell University), Shuang G. Zhao(University of Wisconsin Carbone Cancer Center), Jennifer L. Schehr(University of Wisconsin–Madison), Charlotte N. Stahlfeld(University of Wisconsin–Madison), Jens C. Eickhoff(University of Wisconsin–Madison), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), A. Mitchell(Memorial Sloan Kettering Cancer Center), Alexandre Marcelo Hintz(University of Wisconsin Carbone Cancer Center)
Cited by 7
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k